Abstract
The aim of this study was to determine how good mirabegron is as MET for adults with ureteral stones. The study adhered to the 2020 PRISMA guidelines for Systematic Reviews and Meta-Analyses throughout its duration. Four randomized controlled trial (RCT) studies were included in our analysis, encompassing a total of 369 participants. Our meta-analysis findings indicated that individuals who were administered mirabegron exhibited a statistically significant increase in SER [OR = 2.69, 95% CI 1.16-6.23, p = 0.02] and a reduction in the frequency of pain episodes [MD= -0.18, 95% CI -0.33-(-0.04), p = 0.01] in comparison to those receiving a placebo. However, there was no substantial impact of mirabegron on SET [MD= -3.47, 95% CI -8.65-1.72, p = 0.19] when contrasted with the placebo group. Mirabegron exhibited significantly increased SET levels and reduced pain episodes, although it did not have a significant impact on SER.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
